Specialty Generics Market Size Is Estimated To $174.9 Billion By 2025

The global specialty generics market is expected to reach USD 174.9 billion by 2025, according to a new report by Grand View Research, Inc. Rise in demand for low-cost generic specialty drugs is a major factor estimated to accelerate the market growth during the forecast period. Introduction of cost-effective drugs for the treatment of multiple sclerosis, cancer, and other infectious diseases is expected to showcase huge opportunities for the specialty generic drug manufacturers. According to U.S. FDA, generic drugs cost 80% to 85% lower as compared to branded drugs. One of the factors contributing to their affordable price is that they do not need to repeat expensive clinical trials, advertising, and promotional activities. Thus, low cost of generic specialty drugs is expected to accelerate the demand for these medicines.

Rise in number of off-patent specialty drugs is another major factor expected to support growth of the specialty generic drugs market. For instance, the patent for Gilenya, a blockbuster drug by Novartis, will expire in 2019. This drug led to USD 3.1 billion in sales in 2016 for Novartis, with 14% sales growth. In April 2017, Novartis failed to acquire patent extension for Gilenya till 2026 in the U.S. Federal Circuit. Such early patent expirations are expected to boost the entry of new generics.

Full Research Report On Specialty Generics Market Visit Here: https://www.grandviewresearch.com/industry-analysis/specialty-generics-market

Further Key Findings From the Report Suggest:

• In 2016, injectables was the largest revenue-grossing segment in the market due to its high usage and efficacy in treatment of severe chronic diseases
• The oncology segment accounted for the largest revenue share in 2016 and is expected to maintain its dominance during the forecast period due to worldwide rise in cancer prevalence
• The specialty pharmacy was the largest revenue-generating segment in end use and is estimated to maintain its dominance during the forecast period. This is due to the fact that specialty pharmacies are dedicated to distribution of highlycomplex, costly, and high-touch medicine
• North America dominated the total market in 2016 primarily due to the presence of highly developed healthcare infrastructure and local presence of large number of established pharmaceutical companies
• The Asia Pacific market is estimated to grow at the highest growth rate during the forecast period. Rising prevalence of chronic diseases, developing healthcare infrastructure, and escalating disposable income in Asian countries, such as China and India, are major factors that can be attributed to the growth

• Some of the major players are Teva Pharmaceuticals USA, Inc.; Mylan N.V.; Sandoz International GmbH; Akorn, Inc.; Mallinckrodt; Valeant Pharmaceuticals International, Inc.; Pfizer, Inc.; Endo Pharmaceuticals, Inc.; Apotex Corp.; Sun Pharmaceutical Industries Ltd.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/specialty-generics-market/request/rs1

Grand View Research has segmented the global specialty generic drugs market on the basis of type, application, end-use, and region:

Type Outlook (Revenue, USD Billion; 2014 - 2025)

• Injectables
• Oral
• Others

Application Outlook (Revenue, USD Billion; 2014 - 2025)

• Oncology
• Inflammatory conditions
• Multiple sclerosis
• Hepatitis C
• Others

End-use Outlook (Revenue, USD Billion; 2014 - 2025)

• Specialty pharmacy
• Retail pharmacy
• Hospital pharmacy

Regional Outlook (Revenue, USD Billion; 2014 - 2025)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Asia Pacific
• Japan
• China
• India
• Latin America
• Brazil
• Mexico
• MEA
• South Africa
• Saudi Arabia

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Spinal Muscular Atrophy Treatment Market Size Is Estimated To Reach $3.9 Billion By 2025

The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 3.9 billion by 2025, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 12.9% during the forecast period. Due to the rare nature and complexity of these diseases, scientific knowledge pertaining to them is scarce. However, there are various initiatives undertaken to increase awareness regarding rare diseases and to support SMA communities. This is anticipated to boost market development over the coming years.

Various SMA communities and companies have collaborated for developing disease treatment therapy. For example, RG7916, which is an investigational therapy being developed by Roche in collaboration with SMA Foundation and PTC Therapeutics. Thus, heavy investments in R&D by major companies are also projected to contribute to the growth of this market. CureSMA, SMA Foundation, and SMA Europe are some of the organizations actively supporting R&D pertaining to SMA.

CureSMA provided funding to a research project to Biogen and Ionis Pharmaceuticals, Inc. for developing Spinraza, which received U.S. FDA approval in 2016. This organization has invested nearly USD 70 million in the research pertaining to SMA, which also included a planned investment of USD 5 million in the coming years.

Full Research Report On Spinal Muscular Atrophy Treatment Market Visit Here: https://www.grandviewresearch.com/industry-analysis/spinal-muscular-atrophy-sma-treatment-market

Further key findings from the study suggest:

• The global spinal muscular atrophy treatment market is projected to expand at a CAGR of 12.9% over the forecast period
• Based on disease type, type 1 accounted for the largest revenue share owing to the rising incidence of type 1 SMA
• By treatment, the drug segment accounted for the largest revenue share in 2017
• North America will retain its lead as the largest regional market; however, Asia Pacific is anticipated to register the fastest CAGR over the forecast period
• The market is presently led by Biogen Inc. Biogen’s Spinraza is the only approved commercialized treatment for SMA, owing to which market is not competitive. However, this trend is expected to change after the commercialization of other treatment therapies post-2020

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/spinal-muscular-atrophy-sma-treatment-market/request/rs1

Grand View Research has segmented the global spinal muscular atrophy treatment market on the basis of disease type, treatment, route of administration, and region:

SMA Treatment Disease Type Outlook (Revenue, USD Million, 2015 - 2025)

• Type 1
• Type 2
• Type 3
• Type 4

SMA Treatment Outlook (Revenue, USD Million, 2015 - 2025)

• Gene Therapy
• Drug
• Spinraza
• RG6083 (Olesoxime)
• RG7916

SMA Treatment Route of Administration Outlook (Revenue, USD Million, 2015 - 2025)

• Oral
• Intrathecal

SMA Treatment Regional Outlook (Revenue, USD Million, 2015 - 2025)

• North America
• The U.S.
• Canada
• Europe
• The U.K.
• Germany
• Asia Pacific
• Japan
• China
• Latin America
• Mexico
• Brazil
• Middle East & Africa
• South Africa

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Large Molecule Bioanalytical Testing Service Market Size Is Estimated To Reach $2.6 Billion By 2027

The global large molecule bioanalytical testing service market size is expected to reach USD 2.6 billion by 2027, expanding at a CAGR of 9.1%, according to a new report by Grand View Research, Inc. The major factor attributing to market growth is the increased application of bioanalytical testing in clinical trials of biomarkers, large molecules, and others.

Rising prevalence of HIV, infectious disease, and others has led to increasing demand for bioanalytical testing services globally. Moreover, increasing government initiatives to control the outbreak of various infectious diseases such as Corona and Ebola virus is anticipated to offer more opportunities for the market. Hence, the market is expected to grow over the assessment period.

The market is expected to witness lucrative growth during the forecast period due to increased research activities and the presence of a huge pipeline of peptides, biologics, and amino acids based molecules. Additionally, bioanalysis of large molecules requires skilled professionals with innovative analytical instruments and infrastructure. These services are readily offered by bioanalytical testing service providers and are likely to propel the growth of the market during the assessment period.

North America accounted for the highest share in 2019. The U.S. holds the highest market share due to the increasing prevalence of various chronic diseases and the growing adoption of large molecule therapeutics as an alternative for small molecules.

For example, according to International Diabetes Federation Report 2019, around 49.0 million geriatric population in the U.S. has diabetes and this has led to increasing requests for bioanalysis of the novel (large molecule compounds) peptide therapeutics such as glucagon-like peptide 1(GLP-1). Due to this reason, the market is expected to show growth over the forecast period. In addition, the presence of major players in the region contributed to market growth.

Full Research Report On Large Molecule Bioanalytical Testing Service Market Visit Here: https://www.grandviewresearch.com/industry-analysis/large-molecule-bioanalytical-testing-service-market

Large Molecule Bioanalytical Testing Service Market Report Highlights

• By type, the clinical segment held the largest market share in 2019 owing to increasing demand for clinical trials due to the rising prevalence of various infectious diseases
• Bioavailability held the largest market share of 20.9% in 2019 owing to increasing adoption in generic drug manufacturing
• The oncology segment held the largest revenue share due to the increasing prevalence of cancer globally
• The U.S. is expected to witness the fastest growth over the forecast period owing to the growing adoption of advanced therapeutic techniques in the country.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/large-molecule-bioanalytical-testing-service-market/request/rs1

Large Molecule Bioanalytical Testing Service Market Segmentation

Grand View Research has segmented the global large molecule bioanalytical testing service market based on phase, type, test type, therapeutic area, end-user, and region:

Large Molecule Bioanalytical Testing Service Phase Outlook (Revenue, USD Million, 2016 - 2027)

• Preclinical
• With Antibody
• Without Antibody (ELISA Based Assay)
• Clinical

Large Molecule Bioanalytical Testing Service Type Outlook (Revenue, USD Million, 2016 - 2027)

• Pharmacokinetics
• ADA
• Others

Large Molecule Bioanalytical Testing Service Test Type Outlook (Revenue, USD Million, 2016 - 2027)

• ADME
• PK
• PD
• Bioavailability
• Bioequivalence
• Other Tests

Large Molecule Bioanalytical Testing Service Therapeutic Area Outlook (Revenue, USD Million, 2016 - 2027)

• Oncology
• Infectious Diseases
• Cardiology
• Neurology
• Others

Large Molecule Bioanalytical Testing Service End-user Outlook (Revenue, USD Million, 2016 - 2027)

• SMEs
• CROs & CMOs
• Sponsor Organizations
• Others (Academic institute, etc.)
• Large Firms
• CROs & CMOs
• Sponsor Organizations
• Others (Academic institute, etc.)

Large Molecule Bioanalytical Testing Service Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America
• The U.S.
• Canada
• Europe
• The U.K.
• Germany
• France
• Spain
• Italy
• Asia Pacific
• India
• Japan
• China
• South Korea
• Thailand
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

List of Key Players of Large Molecule Bioanalytical Testing Service Market

• Covance, Inc.
• IQVIA
• Syneos Health
• SGS SA
• Toxikon
• Intertek Group plc
• Pace Analytical Services LLC
• PPD, INC.
• ICON plc
• Charles River Laboratories International

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Healthcare Analytics Market Size Is Projected To Reach $46.1 Billion By 2027

The global healthcare analytics market size is expected to reach USD 46.1 billion by 2027 and is expected to expand at a CAGR of 7.5% over the forecast period, according to a new report by Grand View Research, Inc. Factors, such as the rising number of patient registries, increasing pressure to curb healthcare spending & improve patient outcomes, and extensive usage of big data, data-driven decision-making, & Electronic Health Record (EHRs), are bolstering the market growth. For instance, in August 2020, CitiusTech announced the launch of support for Out-Of-Area (OOA) record collection projects specific to Blue Health Plans through its SCORE+ platform. The launch is aimed at simplifying payer-provider collaboration across states, according to the mandate announced by the Blue Cross Blue Shield Association in December 2019.

The descriptive analytics type segment accounted for the highest revenue share in 2019 owing to the increased adoption of these solutions in analyzing historical data and supporting organizations in improving their performance. On the other hand, predictive analytics is anticipated to be the fastest-growing segment during the forecast period owing to the benefits offered by this solution for effective decision-making to optimize healthcare delivery and reduce costs by eliminating waste, fraud, and abuse. In 2019, the hardware segment accounted for the highest revenue share. On the other hand, the services segment is anticipated to register the fastest growth owing to the prevailing trend of outsourcing among various organizations due to lack of IT professionals, growing adoption of cloud, and increasing awareness regarding healthcare analytics.

Based on delivery mode, on-premises accounted for the largest revenue share in 2019. This is attributed to the level of security & control, and ease of customization offered by the on-premises delivery mode. On the other hand, the cloud-based delivery model is anticipated to be the fastest-growing segment during the forecast period owing to safe storage, extreme capacity flexibility, and the pay-as-you-go pricing facility offered by this model. The financial application segment accounted for the highest revenue share in 2019 owing to various initiatives, including FPS that aids in avoiding frauds & improper payments, and saving costs. Clinical applications are anticipated to be the fastest-growing segment from 2020 to 2027 due to the increasing development & deployment of these solutions for clinical applications to reduce medication errors and healthcare spending while increasing access to clinical data.

In 2019, the healthcare payers end-use segment led the global market. Payers are increasingly adopting these solutions to avoid blind spots and make the best business decisions for their organizations. However, the healthcare providers segment is anticipated to register the fastest CAGR during the forecast period owing to the surge in adoption among providers to offer the right treatment at an effective price, which, in turn, aids in avoiding unnecessary treatment costs. North America is estimated to be the largest regional market due to increasing demand for quality healthcare, improved infrastructure, growing focus on patient safety & care, and the rising awareness about EHRs. Asia Pacific will register the highest CAGR from 2020 to 2027 owing to the growing geriatric population, increasing incidences of chronic diseases, and rising number of government initiatives supporting the adoption of technology-driven tools in the region.

Full Research Report On Healthcare Analytics Market Visit Here: https://www.grandviewresearch.com/industry-analysis/healthcare-analytics-market

Healthcare Analytics Market Report Highlights

• Healthcare analytics market size is anticipated to reach USD 46.1 billion by 2027, owing to a rise in product demand for improving efficiency
• The descriptive analytics type segment dominated the global market in 2019 owing to benefits offered by this solution in analyzing historical data to gain actionable insights
• The hardware component segment dominated the market in 2019 owing to increasing costs associated with the development and deployment of hardware components
• On-premises was the leading delivery mode segment in 2019 owing to enhanced security & control offered by the delivery mode

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/healthcare-analytics-market/request/rs1

Healthcare Analytics Market Segmentation

Grand View Research has segmented the global healthcare analytics market on the basis of type, component, delivery mode, application, end-use, and region:

Healthcare Analytics Type Outlook (Revenue, USD Million, 2014 - 2027)

• Descriptive
• Predictive
• Prescriptive

Healthcare Analytics Component Outlook (Revenue, USD Million, 2014 - 2027)

• Hardware
• Software
• Services

Healthcare Analytics Delivery Mode Outlook (Revenue, USD Million, 2014 - 2027)

• On-premises
• Web-based
• Cloud-based

Healthcare Analytics Application Outlook (Revenue, USD Million, 2014 - 2027)

• Clinical
• Financial
• Operational and Administrative

Healthcare Analytics End-use Outlook (Revenue, USD Million, 2014 - 2027)

• Healthcare Payers
• Healthcare Providers
• Lifescience Companies

Healthcare Analytics Regional Outlook (Revenue, USD Million, 2014 - 2027)

• North America
• U.S.
• Canada
• Europe
• U.K.
• Spain
• Germany
• France
• Italy
• Asia Pacific
• Japan
• China
• India
• South Korea
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

List of Key Players of Healthcare Analytics Market

• IBM Corp.
• OptumHealth, Inc.
• Oracle Corp.
• Verisk Analytics, Inc.
• MEDai, Inc.
• MedeAnalytics, Inc.
• McKesson Corp.
• Truven Health Analytics, Inc.
• Allscripts Healthcare Solutions, Inc.
• Cerner Corporation
• SAS Institute, Inc.

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Anesthesia & Respiratory Devices Market Growth & Trends

The global anesthesia and respiratory devices market size is expected to reach USD 49.4 billion by 2026, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 6.6% over the forecast period. Increasing prevalence of respiratory diseases, patient preferences for reduced hospital stay, and supportive government funding are among the key driving factors.

Shifting preference of patients towards reduced hospital stay is anticipated to increase the adoption of anesthesia and breathing instruments, thereby, driving the market. As per the American Hospital Association, approximately 20% of Medicare beneficiaries, when discharged from hospital return within 30 days. Identifying and reducing avoidable readmissions is expected to improve healthcare safety and reduce spending. Hence, policymakers are striving to reduce hospital stays of patients. The Patient Protection and Affordable Act, Congress initiated the Hospital Readmission Reduction Program (HRRP) under which Medicare is allowed to penalize hospitals for higher rates of readmissions since 2013. Due to the implementation of this act, many physicians and patients opt for anesthesia and breathing devices, such as ambulatory infusion pumps and home respiratory monitors.

Furthermore, aging is considered one of the greatest risk factors for the development of sleep apnea disorders and is therefore, expected to be a high-impact rendering driver for this market.

Key players are also taking initiatives to develop advanced instruments with an aim to bring improvement in the treatment. For instance, in April 2018, B. Braun Medical Inc. announced to introduce Clorotekal, which is a U.S. Food and Drug Administration (FDA) approved anesthetics for spinal anesthesia. Such initiatives are anticipated to propel growth of the anesthesia and respiratory devices market in the forthcoming years.

Full Research Report On Anesthesia & Respiratory Devices Market Visit Here: https://www.grandviewresearch.com/industry-analysis/anesthesia-and-respiratory-devices-market

Anesthesia & Respiratory Devices Market Report Highlights

• On the basis of product, respiratory devices is estimated to expand at the highest CAGR in terms of revenue over the forecast period owing to rising prevalence of cystic fibriosis, asthma, and tuberculosis. Positive airway pressure devices led the segment owing to increasing incidence of Obstructive Sleep Apnea (OSA)
• Asia Pacific is expected to witness the fastest growth over the forecast period owing to increasing healthcare expenditure and awareness among patients
• Few key players operating in the anesthesia and respiratory devices market are AirSep Corporation; B. Braun Medical Inc.; BD; Medtronic; Drager; GE Healthcare; Philips Healthcare; ResMed; and Smiths Medical.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/anesthesia-and-respiratory-devices-market/request/rs1

Anesthesia & Respiratory Devices Market Segmentation

Grand View Research has segmented the global anesthesia and respiratory devices market on the basis of product and region:

Anesthesia & Respiratory Devices Product (Revenue, USD Million, 2015 - 2026)

• Anesthesia Devices
• Machines

• Delivery machines

• Portable
• Standalone
• Monitors
• Ventilators
• Workstations
• Disposables
• Disposables Masks
• Disposable Accessories
• Respiratory Devices
• Equipment
• Positive Airway Pressure
• Bi-level positive airway pressure devices
• Continuous positive airway pressure devices
• Ventilators
• Adult Ventilators
• Neonatal ventilators
• Nebulizers
• Pneumatic nebulizers
• Mesh nebulizers
• Ultrasonic nebulizers
• Humidifiers
• Heat humidifiers
• Heated wire breathing circuits
• Heat exchangers
• Pass over humidifiers
• Inhalers
• Dry powdered inhalers
• Metered dose inhaler
• Oxygen Concentrators
• Fixed oxygen concentrators
• Portable oxygen concentrators
• Reusable Resuscitators
• Disposables
• Disposable Oxygen Masks
• Resuscitators
• Tracheostomy Tubes
• Oxygen Cannula
• Measurement Devices
• Pulse Oximeters
• Capnographs
• Spirometers
• Peak Flow Meters

Anesthesia & Respiratory Devices Regional Outlook (Revenue, USD Million, 2015 - 2026)

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Italy
• France
• Spain
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• MEA
• Saudi Arabia
• South Africa
• UAE

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com